Advertisement
Advertisement
U.S. markets open in 5 hours 26 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Isoray Inc (AAJ.SG)

Stuttgart - Stuttgart Delayed Price. Currency in EUR
0.27600.0000 (0.00%)
As of 09:11AM CEST. Market open.
Advertisement
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Performance Outlook
Previous Close0.2760
Open0.2760
Bid0.2740 x 500000
Ask0.2820 x 500000
Day's Range0.2760 - 0.2760
52 Week Range0.2143 - 0.6500
Volume0
Avg. Volume0
Market CapN/A
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A

Subscribe to Yahoo Finance Plus to view Fair Value for AAJ.SG

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • GlobeNewswire

      Perspective Announces Presentation of Positive Early Clinical Data for VMT-α-NET at the 36th Annual Congress of the European Association of Nuclear Medicine

      Ten patients received therapy, with an initial response seen in 7 out of 9 evaluable patients to date.Responses observed in both peptide receptor radionuclide therapy-naïve and peptide receptor radionuclide therapy-refractory disease. SEATTLE, Wash., Sept. 12, 2023 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), today announced the presentation of encouraging early clinical results from an open-label, single-arm, investigator-initiated s

    • GlobeNewswire

      Perspective Therapeutics to Present at the World Molecular Imaging Congress 2023

      RICHLAND, WASH. & CORALVILLE, IOWA, Aug. 30, 2023 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), today announced that it will have two presentations at the upcoming World Molecular Imaging Congress (WMIC) 2023, hosted by the World Molecular Imaging Society (WMIS). The conference is being held in Prague, Czech Republic, from September 5-9, 2023. “We are pleased with our team’s progress in pioneering the development of promising image-gui

    • GlobeNewswire

      Perspective Therapeutics to Present Clinical and Preclinical Data at the 36th Annual Congress of the European Association of Nuclear Medicine

      RICHLAND, WASH. & CORALVILLE, IOWA, Aug. 28, 2023 (GLOBE NEWSWIRE) -- – Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), today announced that it will present new clinical and preclinical data for 212Pb-VMT-α-NET, a Targeted Alpha-Particle Therapy, at the upcoming 36th Annual Congress of the European Association of Nuclear Medicine (EANM). The conference is being held in Vienna, Austria, from September 9-13, 2023. “Our team at Perspective Therapeutics continu

    Advertisement
    Advertisement